Screener
Spyre Therapeutics, Inc. SYRE Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $97,185 | $85,721 |
| Marketable securities | 644,282 | 670,812 |
| Prepaid expenses and other current assets | 22,486 | 21,248 |
| Total current assets | 763,953 | 777,781 |
| TOTAL ASSETS | $763,953 | $777,781 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s short-term investments?
- Spyre Therapeutics, Inc. (SYRE) reported short-term investments of $644.28M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s short-term investments changed year-over-year?
- Spyre Therapeutics, Inc.'s short-term investments increased by 24.8% year-over-year, from $516.33M to $644.28M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s short-term investments?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s short-term investments has grown at a 64.2% compound annual growth rate (CAGR), from $56.18M to $670.81M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Spyre Therapeutics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude